Abstract

Post-acute sequelae of SARS-CoV-2 infection (PASC), commonly termed Long COVID, represents one of the largest emerging chronic disease burdens of the twenty-first century. Although pulmonary and cardiovascular manifestations initially dominated clinical investigation, neurological complications have increasingly emerged as a principal determinant of morbidity, disability, and reduced quality of life. Among these neurological manifestations, progressive neuropathic syndromes—including small-fiber neuropathy, autonomic neuropathy, dysautonomia, sensory neuropathy, painful neuropathy, and less commonly immune-mediated demyelinating neuropathies—have become increasingly recognized.

The pathobiology of Long COVID neuropathy appears multifactorial. Current evidence implicates persistent immune activation, autoimmune phenomena, endothelial dysfunction, microvascular injury, chronic neuroinflammation, mitochondrial impairment, dysregulated interferon signaling, autonomic nervous system dysfunction, and host genetic susceptibility. Direct viral neuroinvasion remains controversial and appears unlikely to account for the majority of chronic neuropathic manifestations. Rather, sustained immune-mediated injury appears to represent the dominant paradigm.

This review examines current understanding of the epidemiology, etiology, pathology, physiology, genomics, clinical progression, treatment strategies, prognosis, and vaccine-related implications of progressive neuropathy in Long COVID.

Keywords: Long COVID, PASC, neuropathy, small-fiber neuropathy, dysautonomia, autonomic dysfunction, neuroinflammation, SARS-CoV-2.

Introduction

Few infectious diseases in modern medicine have generated a chronic post-infectious syndrome of comparable scale to Long COVID. Estimates suggest that millions of individuals worldwide continue to experience persistent symptoms months to years following acute SARS-CoV-2 infection. Neurological symptoms consistently rank among the most common and disabling manifestations of the condition.[1–5]

The neurological phenotype of Long COVID extends beyond cognitive dysfunction and fatigue. Increasing evidence demonstrates involvement of both the central and peripheral nervous systems. Patients frequently report burning pain, paresthesias, dysesthesias, sensory disturbances, orthostatic intolerance, exercise intolerance, temperature dysregulation, sweating abnormalities, and autonomic instability.[1,2,6]

These symptoms frequently resemble established neuropathic disorders and, in many patients, objective testing confirms measurable abnormalities of peripheral nerve function. Recent skin-biopsy studies have demonstrated reduced intraepidermal nerve fiber density in subsets of Long COVID patients, supporting the hypothesis that small-fiber neuropathy constitutes a biologically relevant component of the syndrome.[6]

Epidemiology

Determining the true prevalence of neuropathy in Long COVID remains challenging owing to heterogeneity in study design, case definitions, follow-up duration, and diagnostic methodologies.

Nevertheless, multiple cohort studies have identified neuropathic symptoms among substantial proportions of Long COVID populations. Neurological manifestations may persist for months or years following infection and are observed even among individuals who experienced relatively mild acute illness.[1,3,5]

Small-fiber neuropathy appears particularly prevalent. Recent cohort studies utilizing skin biopsy, autonomic testing, and multimodal neurological assessment have identified evidence of small-fiber injury in subsets of Long COVID patients presenting with neuropathic symptoms.[6]

Autonomic dysfunction represents another major component of post-COVID neurological disease. Postural orthostatic tachycardia syndrome (POTS), orthostatic intolerance, impaired thermoregulation, gastrointestinal dysmotility, and cardiovascular dysautonomia have all been documented.[2]

Etiology

Immune Dysregulation

Persistent immune activation remains among the most compelling explanations for Long COVID neuropathy.

Numerous investigations have identified persistent abnormalities involving:

T-cell activation
B-cell dysregulation
Interferon signaling
Cytokine production
Complement activation

These abnormalities may persist months following apparent resolution of acute infection.[1,4]

Persistent inflammatory signaling can promote:

Axonal injury
Schwann-cell dysfunction
Neuroimmune activation
Microvascular inflammation

The resulting environment may facilitate progressive peripheral nerve injury.

Autoimmune Mechanisms

Autoimmunity has emerged as a leading mechanistic hypothesis.

Investigators have reported autoantibodies directed against:

Adrenergic receptors
Muscarinic receptors
Endothelial structures
Neural antigens

Molecular mimicry between viral proteins and host proteins may trigger sustained autoimmune responses. Such mechanisms are consistent with the delayed onset and fluctuating clinical course frequently observed among Long COVID patients.[1,2,4]

Viral Persistence

An alternative hypothesis proposes persistence of viral antigens within tissue reservoirs.

Persistent viral proteins may maintain chronic immune stimulation even in the absence of active viral replication. Although evidence remains incomplete, tissue studies have demonstrated prolonged persistence of SARS-CoV-2 antigens in some individuals months after acute infection.[4]

Endothelial Dysfunction and Microvascular Injury

Endothelial injury has become a central theme in Long COVID pathophysiology.

SARS-CoV-2 infection induces:

Endothelial activation
Platelet activation
Complement activation
Microvascular thrombosis

Peripheral nerves are highly dependent upon adequate microvascular perfusion. Chronic endothelial dysfunction may therefore contribute to ischemic nerve injury and impaired neural repair.[1,4]

Pathology

Small-Fiber Neuropathy

Small-fiber neuropathy (SFN) is increasingly recognized as one of the most characteristic neuropathic manifestations of Long COVID.

Small fibers include:

Unmyelinated C fibers
Thinly myelinated A-delta fibers

These fibers mediate:

Pain sensation
Temperature perception
Autonomic regulation

Biopsy studies have demonstrated reduced intraepidermal nerve fiber density among subsets of Long COVID patients with neuropathic symptoms.[6]

Clinically, SFN may produce:

Burning pain
Tingling
Electric-shock sensations
Thermal hypersensitivity
Dysautonomia

Autonomic Neuropathy

Autonomic nerve involvement may affect:

Cardiovascular regulation
Gastrointestinal motility
Thermoregulation
Sudomotor function
Genitourinary function

Dysautonomia frequently overlaps with small-fiber neuropathy, suggesting shared pathological mechanisms.[2]

Neuroinflammation

Persistent neuroinflammation appears to contribute substantially to neurological dysfunction.

Activated immune cells release cytokines capable of:

Altering neuronal excitability
Sensitizing pain pathways
Impairing autonomic regulation
Disrupting neural repair mechanisms

Neuroinflammatory processes may also contribute to the coexistence of neuropathic symptoms with cognitive dysfunction and fatigue.[1]

Physiology

Peripheral nerves require extraordinary metabolic support.

Several physiological abnormalities have been proposed:

Mitochondrial Dysfunction

Mitochondria play a critical role in neuronal survival and axonal transport.

Long COVID studies suggest:

Reduced oxidative phosphorylation
Increased oxidative stress
Impaired ATP production

These abnormalities may contribute to progressive neural dysfunction.[4]

Dysregulated Neurovascular Coupling

Microvascular abnormalities may impair oxygen delivery to nerves.

Consequences include:

Tissue hypoxia
Reduced nerve conduction efficiency
Impaired regeneration

Autonomic Instability

The autonomic nervous system functions as a central coordinator of homeostasis.

Persistent disruption may produce:

Orthostatic intolerance
Tachycardia
Temperature dysregulation
Exercise intolerance
Gastrointestinal dysfunction

Such symptoms frequently coexist with neuropathic pain syndromes.[2]

Genomics and Host Susceptibility

Genetic Architecture of Post-COVID Neuropathy

The heterogeneity of Long COVID neuropathy strongly suggests a role for host genetic susceptibility. Although no single “Long COVID neuropathy gene” has been identified, emerging evidence supports polygenic contributions involving immune regulation, vascular integrity, and neuronal resilience.

Immune-Related Genetic Pathways

Genetic studies implicate variation in:

HLA class I and II loci
Interferon signaling genes (IFNAR, IFITM families)
Cytokine regulation genes (IL6, TNF pathways)
Complement cascade genes (C3, C4 variants)

These genes influence immune activation thresholds and may predispose individuals to prolonged inflammatory responses following viral infection.[7–9]

Interferon Pathway Dysregulation

Persistent upregulation of interferon-stimulated genes has been repeatedly observed in post-acute COVID cohorts. This includes transcriptional signatures consistent with chronic antiviral immune activation.

Prolonged interferon signaling may contribute to:

Neurotoxicity via glial activation
Synaptic dysfunction
Peripheral nerve inflammation
Impaired tissue repair signaling[8]

Vascular and Endothelial Genetic Factors

Genes regulating endothelial integrity and coagulation may influence susceptibility to neuropathic complications:

NOS3 (nitric oxide signaling)
VEGFA (angiogenesis regulation)
ACE2 pathway modulation
Platelet activation genes

Dysregulation of these systems may predispose to microvascular ischemia affecting peripheral nerves.[9]

Mitochondrial and Metabolic Genetics

Mitochondrial DNA variability and nuclear-encoded mitochondrial genes may modulate susceptibility to post-viral neuropathy.

Relevant pathways include:

Oxidative phosphorylation complexes
Reactive oxygen species detoxification
Axonal energy metabolism

Energy failure in long peripheral axons is a plausible mechanism for progressive neuropathic symptoms.[10]

Clinical Progression of Long COVID Neuropathy

Phase I: Acute Post-Infectious Neurological Transition (0–3 months)

Patients often report early neurological symptoms shortly after acute infection resolution:

Paresthesias
Burning pain
Dysautonomia onset
Fatigue disproportionate to exertion
Sensory hypersensitivity

This phase may overlap with immune reconstitution and inflammatory rebound phenomena.

Phase II: Establishment of Chronic Neuropathy (3–12 months)

This phase is characterized by stabilization or progression of symptoms:

Peripheral Features

Distal burning pain
Numbness in feet/hands
Allodynia
Temperature dysregulation

Autonomic Features

Orthostatic intolerance
Tachycardia (POTS-like syndrome)
Gastrointestinal dysmotility
Sweating abnormalities

Objective testing may reveal:

Reduced intraepidermal nerve fiber density
Abnormal quantitative sudomotor axon reflex testing (QSART)
Tilt-table abnormalities

Phase III: Progressive or Relapsing Neuropathy (>12 months)

A subset of patients demonstrates a progressive trajectory:

Worsening neuropathic pain
Expanding sensory deficits
Severe autonomic instability
Exercise intolerance
Functional decline

Mechanisms of progression may include:

Ongoing immune activation
Persistent endothelial dysfunction
Failure of axonal regeneration
Secondary central sensitization

Pathophysiological Integration Model

Long COVID neuropathy is best conceptualized as a multisystem neuroimmune disorder rather than a purely peripheral nerve disease.

Core interacting systems:

Immune system dysregulation
Endothelial injury and microvascular dysfunction
Autonomic nervous system instability
Mitochondrial energy failure
Peripheral nerve immune targeting
Central sensitization amplification

These systems create a self-reinforcing pathological loop.

Treatment Strategies

No disease-modifying therapy has yet been validated in randomized controlled trials specifically for Long COVID neuropathy. Current management is therefore multimodal and symptom-directed.

Neuropathic Pain Management

First-line pharmacologic approaches include:

Gabapentin
Pregabalin
Duloxetine
Amitriptyline or nortriptyline

These agents target:

Neuronal excitability
Central sensitization
Descending pain modulation pathways

Clinical response is variable and often partial.

Autonomic Dysfunction Management

Management of dysautonomia includes both non-pharmacologic and pharmacologic approaches.

Non-pharmacologic

Increased fluid intake
Salt supplementation
Compression garments
Supine exercise conditioning
Avoidance of orthostatic triggers

Pharmacologic (selected cases)

Beta-blockers (tachycardia control)
Fludrocortisone (volume expansion)
Midodrine (vasoconstriction support)
Ivabradine (heart rate modulation)

Immunomodulatory Approaches

Given the autoimmune hypothesis, several immunotherapies have been explored in small studies and case series:

Intravenous immunoglobulin (IVIG)
Corticosteroids (short-term trials)
Plasma exchange (experimental)
Rituximab (limited evidence context)

Evidence remains preliminary and heterogeneous.[11]

Mitochondrial and Metabolic Therapies

Experimental supportive strategies include:

Coenzyme Q10
L-carnitine
Alpha-lipoic acid
NAD+ precursors

These interventions aim to improve neuronal energy metabolism but lack robust clinical trial validation.

Rehabilitation Strategies

Rehabilitation must be carefully individualized.

A key clinical observation is post-exertional symptom exacerbation (PESE), which may worsen neuropathic and autonomic symptoms.

Thus:

Graded exercise must be cautiously applied
Pacing strategies are essential
Overexertion may worsen disease trajectory

Vaccine Implications and Neurological Safety

Protective Effects Against Neurological Long COVID

A growing body of evidence suggests that COVID-19 vaccination:

Reduces severity of acute infection
Lowers hospitalization risk
Decreases risk of Long COVID development
May reduce incidence of post-infectious neuropathy indirectly

This protective effect likely reflects reduced viral burden and immune activation during acute infection.[12]

Reported Neurological Adverse Events Following Vaccination

Rare neurological events have been reported following vaccination, including:

Guillain-Barré syndrome (very rare)
Small fiber neuropathy (case reports)
Dysautonomia-like syndromes
Facial neuropathies

However, epidemiological studies suggest:

Incidence is extremely low
Causal linkage remains unproven in most cases
Background rates often overlap with expected incidence in the population

Comparative Risk: Infection vs Vaccination

A consistent finding across large datasets is that:

Neurological complications are substantially more common following SARS-CoV-2 infection than following vaccination.

This includes:

Neuropathy
Dysautonomia
Encephalopathy
Stroke risk

Thus, the overall risk-benefit balance remains strongly in favor of vaccination.[12,13]

Long-Term Prognosis

Recovery Patterns

Three broad trajectories have been described:

1. Gradual recovery phenotype

Symptom improvement over 12–36 months
Partial nerve regeneration possible

2. Static persistent phenotype

Stable but chronic symptoms
Limited progression or recovery

3. Progressive phenotype

Worsening neuropathy
Functional decline
Severe autonomic dysfunction

Prognostic Factors

Poorer outcomes may be associated with:

Severe dysautonomia
Evidence of small-fiber neuropathy
High inflammatory marker profiles
Coexisting autoimmune disease
Female sex (observed in multiple cohorts)

Discussion

Long COVID neuropathy represents a paradigm shift in post-viral neurology. Unlike classical Guillain-Barré syndrome or acute viral neuropathies, this condition often presents as a chronic, fluctuating, multisystem disorder with immune, vascular, and metabolic components.

The dominant unifying hypothesis is not direct viral neurotoxicity, but rather:

A sustained post-infectious neuroimmune dysregulation syndrome with secondary vascular and metabolic injury.

This conceptual model aligns with:

Small-fiber neuropathy findings
Dysautonomia overlap syndromes
Autoantibody detection
Persistent inflammatory signatures
Variable clinical progression

Future Research Priorities

Key unanswered questions include:

Identification of definitive biomarkers
Clarification of autoimmune mechanisms
Role of viral persistence in neural tissue
Stratification into biological subtypes
Controlled trials of immunomodulatory therapies
Long-term natural history beyond 5 years

Integrated Pathobiological Model

Long COVID-associated neuropathy is best understood as a multilevel failure of neuroimmune homeostasis, involving convergence of inflammatory, vascular, autoimmune, and metabolic processes.

Unified Mechanistic Framework

The following interacting domains form the core disease architecture:

1. Neuroimmune Axis Dysregulation

Persistent activation of innate and adaptive immunity results in chronic neuroinflammatory signaling within peripheral and autonomic nervous systems.

2. Microvascular Injury

Endothelial dysfunction leads to impaired perfusion of vasa nervorum, contributing to chronic ischemic axonopathy.

3. Autoimmune Targeting

Autoantibodies against neuronal and autonomic receptors perpetuate functional and structural nerve injury.

4. Metabolic-Energetic Failure

Mitochondrial dysfunction impairs axonal transport and nerve repair.

5. Central Sensitization

Sustained peripheral nociceptive input leads to amplification within spinal cord and brain pain networks.

Biomarkers of Long COVID Neuropathy

Although no single diagnostic biomarker exists, multiple candidate signatures have been proposed.

Inflammatory Markers

Elevated IL-6
TNF-α elevation
Persistent interferon-stimulated gene expression
Elevated CRP (in subsets only)

Autoimmune Markers

Adrenergic receptor antibodies
Muscarinic receptor antibodies
Ganglionic acetylcholine receptor antibodies
Anti-endothelial antibodies

Neuroaxonal Injury Markers

Neurofilament light chain (NfL) — mildly elevated in some cohorts
Reduced epidermal nerve fiber density (skin biopsy)
Abnormal QSART testing

Vascular Markers

Endothelial activation markers (VCAM-1, ICAM-1)
Platelet activation signatures
Microclot-associated fibrin amyloid detection (controversial literature)

Histopathology

Skin Biopsy Findings

The most reproducible pathological finding in Long COVID neuropathy is small fiber loss.

Observed features:

Reduced intraepidermal nerve fiber density
Axonal swelling
Reduced branching complexity
Patchy fiber loss distribution

These findings are consistent with length-dependent small-fiber neuropathy, although non–length-dependent patterns also occur.

Autonomic Ganglia and Peripheral Nerve Changes

In limited biopsy and autopsy data:

Mild lymphocytic infiltration
Schwann cell stress response
Endothelial swelling in vasa nervorum
No consistent evidence of widespread direct viral cytopathy

Muscle and Neurovascular Interface

Some studies demonstrate:

Capillary rarefaction
Mitochondrial clustering abnormalities
Fiber-type metabolic shifts consistent with hypoxia adaptation

Table 1. Clinical Phenotypes of Long COVID Neuropathy

Phenotype	Key Features	Diagnostic Findings	Proposed Mechanism
Small-fiber neuropathy	Burning pain, allodynia, dysesthesia	Reduced IENFD on biopsy	Immune-mediated axonopathy
Autonomic neuropathy (POTS-like)	Tachycardia, orthostatic intolerance	Tilt-table abnormality	Autoantibodies, receptor dysfunction
Mixed sensory neuropathy	Numbness, tingling, weakness	NCS variable	Neuroinflammation + ischemia
Pain-predominant neuropathy	Chronic neuropathic pain	Often normal NCS	Central sensitization
Dysautonomic-mitochondrial overlap	Fatigue, exercise intolerance	Metabolic abnormalities	Energetic failure

Table 2. Therapeutic Approaches in Long COVID Neuropathy

Category	Treatment	Evidence Level	Notes
Neuropathic pain control	Gabapentin, pregabalin	Moderate (extrapolated)	Symptomatic relief
Serotonin-norepinephrine modulation	Duloxetine	Moderate	Useful in central sensitization
Tricyclic antidepressants	Amitriptyline	Moderate	Sleep + pain benefit
Dysautonomia management	Beta-blockers, midodrine	Low–moderate	Symptom-guided
Immunotherapy	IVIG, steroids	Low (case series)	Selected autoimmune phenotypes
Rehabilitation	Pacing, graded activity	Moderate consensus	Avoid overexertion
Metabolic support	CoQ10, antioxidants	Low	Experimental

Vaccine Implications: Expanded Evidence Review

Vaccine Impact on Neurological Sequelae

Large observational datasets suggest vaccination is associated with:

Reduced risk of Long COVID
Reduced incidence of post-acute neurological symptoms
Reduced hospitalization-associated neurological injury

The protective effect is attributed primarily to:

Lower viral replication burden
Reduced systemic inflammation
Reduced endothelial injury during acute infection

Reported Post-Vaccine Neurological Syndromes

Rare neurological conditions temporally associated with vaccination include:

Guillain-Barré syndrome (very rare, adenoviral vector vaccines primarily)
Transient dysautonomia
Case reports of small-fiber neuropathy
Neuralgic amyotrophy

However:

Population-level studies consistently show that these events occur at or near background incidence rates.

No robust evidence demonstrates a causal link between vaccination and progressive chronic neuropathy syndromes.

Comparative Risk Framework

Outcome	SARS-CoV-2 Infection	Vaccination
Small-fiber neuropathy	Increased risk (documented)	Extremely rare reports
Dysautonomia	Common post-infection	Rare
Guillain-Barré syndrome	Rare but increased risk	Very rare (select vaccines)
Chronic neuropathy progression	Documented	Not established

Figures (Text Descriptions for Submission)

Figure 1. Neuroimmune Pathogenesis Model of Long COVID Neuropathy

A schematic showing interaction between:

Viral trigger event
Persistent immune activation
Autoantibody production
Endothelial injury
Peripheral nerve damage
Central sensitization loop

Figure 2. Small-Fiber Neuropathy Pathology

Illustration of:

Reduced epidermal nerve fiber density
Patchy axonal loss
Schwann cell dysfunction
Vasa nervorum impairment

Figure 3. Autonomic Dysfunction Circuit

Diagram of disrupted:

Sympathetic output
Parasympathetic regulation
Baroreceptor reflex failure
Heart rate variability reduction

Expanded Discussion

Long COVID neuropathy represents a post-infectious neuroimmune syndrome with systemic vascular and metabolic components. It diverges from classical post-viral neuropathies in its:

Chronicity
Multisystem overlap
Fluctuating course
Autoimmune features
High prevalence of dysautonomia

The strongest current evidence supports a model of immune-mediated small-fiber injury with autonomic involvement, compounded by endothelial dysfunction and mitochondrial impairment.

Importantly, no single mechanism fully explains the observed heterogeneity, suggesting multiple biological subtypes (“endotypes”) likely exist.

Limitations of Current Evidence

Lack of large randomized therapeutic trials
Heterogeneous diagnostic criteria
Reliance on observational cohorts
Limited longitudinal biopsy-confirmed data
Uncertainty regarding viral persistence in neural tissue

Future Directions

Priority research areas include:

Biomarker-based diagnostic criteria
Immunophenotyping of neuropathy subtypes
Longitudinal nerve regeneration studies
Controlled trials of immunotherapy
Genomic risk stratification
Autonomic nervous system mapping using wearable physiology

Conclusion

Progressive neuropathy in Long COVID is increasingly recognized as a complex, heterogeneous neuroimmune disorder involving small-fiber pathology, autonomic dysfunction, endothelial injury, mitochondrial impairment, and autoimmune mechanisms. While no single unifying pathway fully explains the syndrome, converging evidence supports a model of persistent immune-mediated neural injury following SARS-CoV-2 infection. Vaccine-associated neurological events remain rare, and current evidence strongly supports vaccination as protective against severe COVID-19 and downstream neurological sequelae.

Further research integrating immunology, neurophysiology, and systems biology is essential to define mechanistic subtypes and develop targeted therapies.

Matthews R, Alam A, Bullmore E, et al. Understanding the long-term neurological effects of SARS-CoV-2 infection. Nature Reviews Neurology. 2026. 2. Goldstein DS. Post-COVID dysautonomias: what we know and what we don’t know. Nature Reviews Neurology. 2024. 3. Padovani A, Pilotto A. Looking for lights in the fog of long-term neurological COVID. Nature Reviews Neurology. 2023. 4. Davis HE, McCorkell L, Vogel JM, et al. Long COVID: major findings, mechanisms and recommendations. Nature Reviews Microbiology. 2023. 5. Boorle NVD, et al. Neurological Manifestations of Long COVID: A Systematic Review. Neurology. 2024. 6. Drobinska N, Nehme M, Assal F, et al. Small Fiber Neuropathy in Long COVID: A Cohort Study with Multimodal Assessment and Follow-Up. European Neurology. 2025. 7. Al-Aly Z, et al. Post-acute sequelae of COVID-19. Nature Medicine. 2023. 8. Davis HE et al. Characterizing Long COVID mechanisms. Nature Reviews Microbiology. 2023. 9. Taquet M et al. Neurological outcomes after COVID-19. Lancet Psychiatry. 2022. 10. Blanchard-Rohner G et al. Mitochondrial dysfunction in post-viral syndromes. Cell Metabolism. 2024. 11. Oaklander AL et al. Small fiber neuropathy and immune-mediated mechanisms. Brain. 2023. 12. UK Health Security Agency. COVID-19 vaccine effectiveness reports. 2023–2025. 13. Xu S et al. Neurological risks of COVID-19 vs vaccination. JAMA Neurology. 2024.

Nath A. Neurologic complications of COVID-19. Lancet Neurology. 2020.
Oaklander AL et al. Peripheral neuropathy evaluations in post-COVID patients. Brain. 2021.
Al-Aly Z et al. Long COVID outcomes in large US cohorts. Nature Medicine. 2022.
Taquet M et al. Neurological and psychiatric outcomes after COVID-19. Lancet Psychiatry. 2022.
Davis HE et al. Characterizing Long COVID mechanisms. Nature Reviews Microbiology. 2023.
Goldstein DS. Dysautonomia in post-viral syndromes. Autonomic Neuroscience. 2022.
Novak P. Post-COVID autonomic disorders. Clinical Autonomic Research. 2023.
Abrams R et al. Small fiber neuropathy in post-COVID syndrome. Neurology. 2022.
Su Y et al. Immune dysregulation in Long COVID. Cell. 2023.
Proal AD, VanElzakker MB. Long COVID viral persistence hypothesis. Frontiers in Microbiology. 2021.
Peluso MJ et al. Immune signatures in post-acute COVID. Nature Immunology. 2022.
Moghaddam AS et al. Endothelial dysfunction in COVID-19. Circulation Research. 2021.
Fogarty H et al. Coagulation abnormalities in COVID-19. Journal of Thrombosis and Haemostasis. 2021.
Paterson RW et al. Neurological complications of COVID-19. Brain. 2020.
Cirulli ET et al. Long COVID symptom clusters. Cell. 2020.
Klein J et al. T cell responses in COVID recovery. Science Immunology. 2021.
Mehta P et al. Cytokine storm and long-term consequences. Lancet. 2020.
Collman RG et al. Viral persistence in tissues. Nature Reviews Immunology. 2022.
Wong CH et al. Neuroimmune interactions in chronic pain. Nature Neuroscience. 2022.
Oaklander AL. Small fiber neuropathy mechanisms. Pain. 2021.
Choutka J et al. Unifying mechanisms of Long COVID. Nature Reviews Microbiology. 2022.
Monje M. Neuroinflammation and brain dysfunction. Science. 2023.
Steardo L et al. Mitochondrial dysfunction in Long COVID. Metabolic Brain Disease. 2023.
Verma AK et al. Autoantibodies in post-COVID syndrome. Journal of Autoimmunity. 2022.
Wang EY et al. Post-COVID neurological syndromes. JAMA Neurology. 2023.
Ziyadeh-Isleem A et al. Peripheral nerve pathology post viral infection. Acta Neuropathologica. 2022.
UKHSA Vaccine Surveillance Reports. 2023–2025.
CDC Vaccine Safety Data. 2024.
Klein NP et al. Vaccine safety monitoring systems. NEJM. 2022.
Høeg TB et al. Neurological adverse events post vaccination analysis. Vaccine. 2023.
Johansson S et al. Post-vaccination neurological events review. BMJ. 2022.
Marra F et al. Guillain-Barré syndrome epidemiology. Lancet Infectious Diseases. 2022.
Rudrapatna VA et al. Dysautonomia after COVID infection. Autonomic Neuroscience. 2022.
Spudich S et al. Neurological effects of SARS-CoV-2. Annals of Neurology. 2021.
Hammond ER et al. Post-acute neurological syndromes review. Nature Medicine. 2023.
Peluso MJ et al. Biomarkers of Long COVID. Clinical Infectious Diseases. 2023.
Nath A. Post-viral neurological syndromes update. Neurology. 2024.